Lennart Lenk

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 13

Top Venues

Blood advances

Blood

Leukemia

This page only lists publications with an associated author ORCID identifier.

Publications

Gaia Gentile, Teresa Poggio, Antonella Catalano, Minna Voutilainen, Mari Lahnalampi, Marta Andrade-Martinez, Tobias Ma, Roman Sankowski, Lina Goncharenko, Stefan Tholen, Kyuho Han, David W Morgens, Marco Prinz, Michael Lübbert, Sophia Engel, Tanja Nicole Hartmann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Stanulla, Justus Duyster, Peter Bronsert, Michael Bassik, Michael L Cleary, Oliver Schilling, Merja Heinäniemi, Jesus Duque-Afonso
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL. Blood advances (2024)
Gaia Gentile, Teresa Poggio, Antonella Catalano, Minna Voutilainen, Mari Lahnalampi, Marta Andrade-Martinez, Tobias Ma, Roman Sankowski, Lina Goncharenko, Stefan Tholen, Kyuho Han, David W Morgens, Marco Prinz, Michael Lübbert, Sophia Engel, Tanja Nicole Hartmann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Stanulla, Justus Duyster, Peter Bronsert, Michael C Bassik, Michael L Cleary, Oliver Schilling, Merja Heinäniemi, Jesus Duque-Afonso
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL. Blood advances 8 (11) (2024)
Philip Gebing, Stefanos Loizou, Sebastian Hänsch, Julian Schliehe-Diecks, Lea Spory, Pawel Stachura, Vera H Jepsen, Melina Vogt, Aleksandra A Pandyra, Herui Wang, Zhengping Zhuang, Johannes Zimmermann, Martin Schrappe, Gunnar Cario, Ameera Alsadeq, Denis M Schewe, Arndt Borkhardt, Lennart Lenk, Ute Fischer, Sanil Bhatia
A brain organoid/ALL co-culture model reveals the AP-1 pathway as critically associated with CNS involvement of BCP-ALL. Blood advances (2024)
Gaia Gentile, Teresa Poggio, Antonella Catalano, Minna Voutilainen, Mari Lahnalampi, Marta Andrade-Martinez, Tobias Ma, Roman Sankowski, Lina Goncharenko, Stefan Tholen, Kyuho Han, David W Morgens, Marco Prinz, Michael Lübbert, Sophia Engel, Tanja Nicole Hartmann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Stanulla, Justus Duyster, Peter Bronsert, Michael C Bassik, Michael L Cleary, Oliver Schilling, Merja Heinäniemi, Jesus Duque-Afonso
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL. Blood advances 8 (11) (2024)
Lennart Lenk, Irène Baccelli, Anna Laqua, Julia Heymann, Claas Reimer, Anna Dietterle, Dorothee Winterberg, Caroline Mary, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Stéphanie Neyton, Mylène Déramé, Sabrina Pengam, Fotini Vogiatzi, Beat C Bornhauser, Jean-Pierre Bourquin, Simon Raffel, Vladyslava Dovhan, Thomas Schüler, Gabriele Escherich, Monique L Den Boer, Judith M Boer, Wiebke Wessels, Matthias Peipp, Julia Alten, Željko Antić, Anke Katharina Bergmann, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood 143 (26) (2024)
Philip Gebing, Stefanos Loizou, Sebastian Hänsch, Julian Schliehe-Diecks, Lea Spory, Pawel Stachura, Vera H Jepsen, Melina Vogt, Aleksandra A Pandyra, Herui Wang, Zhengping Zhuang, Johannes Zimmermann, Martin Schrappe, Gunnar Cario, Ameera Alsadeq, Denis M Schewe, Arndt Borkhardt, Lennart Lenk, Ute Fischer, Sanil Bhatia
A brain organoid/ALL co-culture model reveals the AP-1 pathway as critically associated with CNS involvement of BCP-ALL. Blood advances (2024)
Gaia Gentile, Teresa Poggio, Antonella Catalano, Minna Voutilainen, Mari Lahnalampi, Marta Andrade-Martinez, Tobias Ma, Roman Sankowski, Lina Goncharenko, Stefan Tholen, Kyuho Han, David W Morgens, Marco Prinz, Michael Lübbert, Sophia Engel, Tanja Nicole Hartmann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Stanulla, Justus Duyster, Peter Bronsert, Michael C Bassik, Michael L Cleary, Oliver Schilling, Merja Heinäniemi, Jesus Duque-Afonso
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL. Blood advances 8 (11) (2024)
Gaia Gentile, Teresa Poggio, Antonella Catalano, Minna Voutilainen, Mari Lahnalampi, Marta Andrade-Martinez, Tobias Ma, Roman Sankowski, Lina Goncharenko, Stefan Tholen, Kyuho Han, David W Morgens, Marco Prinz, Michael Lübbert, Sophia Engel, Tanja Nicole Hartmann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Stanulla, Justus Duyster, Peter Bronsert, Michael C Bassik, Michael L Cleary, Oliver Schilling, Merja Heinäniemi, Jesus Duque-Afonso
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL. Blood advances 8 (11) (2024)
Lennart Lenk, Irène Baccelli, Anna Laqua, Julia Heymann, Claas Reimer, Anna Dietterle, Dorothee Winterberg, Caroline Mary, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Stéphanie Neyton, Mylène Déramé, Sabrina Pengam, Fotini Vogiatzi, Beat C Bornhauser, Jean-Pierre Bourquin, Simon Raffel, Vladyslava Dovhan, Thomas Schüler, Gabriele Escherich, Monique L Den Boer, Judith M Boer, Wiebke Wessels, Matthias Peipp, Julia Alten, Željko Antić, Anke Katharina Bergmann, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood 143 (26) (2024)
Lennart Lenk, Irène Baccelli, Anna Laqua, Julia Heymann, Claas Reimer, Anna Dietterle, Dorothee Winterberg, Caroline Mary, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Stéphanie Neyton, Mylène Déramé, Sabrina Pengam, Fotini Vogiatzi, Beat C Bornhauser, Jean-Pierre Bourquin, Simon Raffel, Vladyslava Dovhan, Thomas Schüler, Gabriele Escherich, Monique L Den Boer, Judith M Boer, Wiebke Wessels, Matthias Peipp, Julia Alten, Željko Antić, Anke Katharina Bergmann, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood 143 (26) (2024)
Lennart Lenk, Irène Baccelli, Anna Laqua, Julia Heymann, Claas Reimer, Anna Dietterle, Dorothee Winterberg, Caroline Mary, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Stéphanie Lara Neyton, Mylène Déramé, Sabrina Pengam, Fotini Vogiatzi, Beat Bornhauser, Jean-Pierre Bourquin, Simon Raffel, Vladyslava Dovhan, Thomas Schüler, Gabriele Escherich, Monique L den Boer, Judith M Boer, Wiebke Wessels, Matthias Peipp, Julia Alten, Željko Antić, Anke Katharina Bergmann, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis M Schewe
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis. Blood (2024)
Željko Antić, Alena van Bömmel, Konstantin Riege, Jana Lentes, Charlotte Schröder, Julia Alten, Cornelia Eckert, Lara Fuhrmann, Doris Steinemann, Lennart Lenk, Denis Martin Schewe, Martin Zimmermann, Martin Schrappe, Brigitte Schlegelberger, Gunnar Cario, Steve Hoffmann, Anke Katharina Bergmann
Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALL. Leukemia (2023)
Sophie Steinhäuser, Patricia Silva, Lennart Lenk, Thomas Beder, Alina Hartmann, Sonja Hänzelmann, Lars Fransecky, Martin Neumann, Lorenz Bastian, Simone Lipinski, Kathrin Richter, Miriam Bultmann, Emely Hübner, Shuli Xia, Christoph Röllig, Fotini Vogiatzi, Denis Martin Schewe, Veronica Yumiceba, Kristin Schultz, Malte Spielmann, Claudia Dorothea Baldus
Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML). Leukemia (2022)

Lennart Lenk.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lennart Lenk